canaloplasty to
the next level.

The iTrack™ Advance Advantage

For over a decade, Nova Eye’s proprietary iTrack™ canaloplasty microcatheter has been used across the globe, combining pressurized viscodilation with catheterization over the entire 360º of the conventional outflow pathway, to effectively treat more than 100,000 glaucoma patients.* Building on that success and the clinically proven effectiveness of the iTrack™ technology1,2, we are proud to introduce the next generation of iTrack™ – iTrack™ Advance.

The ground-breaking iTrack™ Advance takes the established effectiveness,1,2 accuracy and reliability of the original iTrack™ canaloplasty microcatheter, and combines it with an ergonomic, easy-to-use handheld injector.

The iTrack™ Advance has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. 

iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.


Developed out of extensive research, innovation and feedback from surgeons, the iTrack™ Advance’s all-in-one handheld injector allows for streamlined insertion of the microcatheter into Schlemm’s canal. It also enables predictable, controlled and smooth advancement/​retraction of the microcatheter through the canal. The clinically proven1,2 iTrack™ microcatheter is at the heart of the iTrack™ Advance. Measuring just 220 microns in diameter, it comprises a sophisticated set of inner workings including a proprietary fiber optic for illuminating the distal tip.


Spatulated tip design for ease of access into Schlemm's canal.


Nozzle can be rotated 360° to precisely position the cannula.


Smooth gliding mechanism for precise advancement and retraction of microcatheter during canal intubation and withdrawal.

Polymer Shaft

220-micron shaft with lubricious coating for 360° cannulation of Schlemm’s canal.

Infusion Pathway

Infusion pathway that connects to ViscoInjector™ OVD delivery system.

Guidewire Mechanism

Internal guidewire to push through adhesions and to move through tight areas or structures of the canal.

Optical Fiber

Optical Fiber connects to the portable iLumin™ light source.

Illuminated Tip

Proprietary illuminated tip for transluminal visualization of the microcatheter through every procedural step.

The canaloplasty device in a league of its own.

The unique design of the iTrack™ Advance allows you to perform canaloplasty over the entire 360º of the conventional outflow pathway via a single intubation. Utilizing a process of catheterization and pressurized viscodilation, iTrack™ Advance is designed to stretch the trabecular meshwork and create microperforations into the anterior chamber, and to remove herniations of the collector channel ostia.3,4,5

Ultimately, it’s canaloplasty without compromise.


iTrack™ Advance delivers 100+ microliters of OVD* over 360° of the canal.*

* Testing using a robotically controlled ViscoInjector™ with time-recording mass data to simulate the delivery of OVD over 360° of Schlemm’s canal. Data available upon request.


iTrack™ Advance delivers OVD into Schlemm’s canal via a patented, pressurized mechanism (Patent No. US7,967,772,B2).

360 degree canaloplasty

With a flexible design and internal guide-wire, iTrack™ Advance can catheterize and viscodilate 360° of the canal in a single intubation


A proprietary illuminated fiber optic tip to the microcatheter provides continuous location feedback and safeguards against misdirection of the iTrack™ Advance into the suprachoroidal space or the collector channels.

Canaloplasty for implant-free, 360º glaucoma treatment

Inspired by the success and methodology of modern angioplasty, Nova Eye pioneered canaloplasty for glaucoma in 2008 with the launch of the rigorously tested iTrack™ procedure, which combines 360° catheterization and pressurized viscodilation to treat all points of outflow resistance – reducing IOP to the low-teens.1 Stent-free and tissue-preserving, canaloplasty can help glaucoma surgeons, comprehensive ophthalmologists and cataract specialists effectively reduce IOP in cases of mild to moderate glaucoma, while preserving the viability of future treatment options. 

As a 360° procedure that addresses the entire conventional outflow pathway, including the trabecular meshwork, Schlemm’s canal and the collector channels,3,4,5iTrack™ Advance literally treats glaucoma from all angles.

What’s more, iTrack™ Advance is cleared for use as a standalone procedure and in combination with cataract surgery.

By maintaining the natural pathway of aqueous outflow, iTrack™ Advance lets you work with patient physiology, not against it.

iTrack Advance procedure for glaucoma

In this video, Dr Nathan Kerr performs and describes the iTrack Advance procedure for the treatment of primary open angle glaucoma.

1. Gallardo MJ. 36-month effectiveness of ab-interno canaloplasty standalone versus combined with cataract surgery for the treatment of open-angle glaucoma. Ophthalmol Glaucoma. 2022 Feb 17:S2589-4196(22)00025 – 4.2. Khaimi, M. A., Dvorak, J. D., & Ding, K. (2017). An analysis of 3‑year outcomes following canaloplasty for the treatment of open-angle glaucoma. Journal of ophthalmology, 2017.3. Smit BA, Johnstone MA. Effects of viscoelastic injection into Schlemm’s canal in primate and human eyes: potential relevance to viscocanalostomy. Ophthalmology. 2002;109(4):786 – 792.4. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316 – 322.5. Johnstone MA, Grant WM. Microsurgery of Schlemm’s canal and the human aqueous outflow system. Am J Ophthalmol 1973;76:906 – 17.* Company estimate based on sales figures for the iTrack canaloplasty microcatheter from 2008 – 2022


This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More